Aberrant activation of NF-κB is frequently seen in tumor cells, including cervical cancer cells, and is believed to be one of the reasons for the development of resistance mechanisms that contribute to resistance to current chemo- and radiotherapies [11–13]. The gene discussed is NFKB1; the disease is cervical carcinoma.